- Home
- VACI vs BNR Comparison
VACI vs BNR Comparison
Compare VACI & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VACI | BNR |
|---|---|---|
| Founded | 2025 | 2014 |
| Country | United States | China |
| Employees | N/A | 674 |
| Industry | Telecommunications Equipment | Medical Specialities |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 310.8M | 252.7M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | VACI | BNR |
|---|---|---|
| Price | $9.96 | $22.81 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 75.1K | 13.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $136.32 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.86 | $2.18 |
| 52 Week High | $10.07 | $41.72 |
Technical Indicators
Market Signals| Indicator | VACI | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 52.24 | 40.95 |
| Support Level | $9.94 | $7.99 |
| Resistance Level | $9.97 | $24.23 |
| Average True Range (ATR) | 0.02 | 2.07 |
| MACD | -0.00 | -0.41 |
| Stochastic Oscillator | 60.00 | 29.88 |
Price Performance
Historical ComparisonAbout VACI Viking Acquisition Corp. I Class A Ordinary Shares
Viking Acquisition Corp I is a blank check company.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.